Introducere. Infecţia cu SARS-CoV-2 se poate manifesta prin simptome reumatologice, care ulterior ar putea evolua spre o potenţială maladie sistemică. Scopul. Identificarea pe termen lung a consecinţelor morbide de tip reumatologie la pacienţii care au suferit COVID-19. Metode. Au fost urmăriţi 58 de pacienţi, cu vârste între 18 şi 78 de ani, care au suferit COVID-19 (aa. 2019-2022) şi au manifestat simptome clinice reumatice în timpul infecţiei active şi în perioada reconvalescentă (>2 săptămâni), fiind monitorizaţi la 6 luni, 1 an şi 2 ani. Severitatea evoluţiei COVID-19 variind de la subclinică la forme grave cu leziuni pulmonare extinse. Rezultate. în perioada infecţiei active şi de reconvalescenţă, au predominat mialgiile la toţi 58 (100%) pacienţi, artralgiile la 52 (89%), rahialgiile la 44 de pacienţi (75,8%); artrite au avut 5 pacienţi (8,6%), iar 3 pacienţi (5,7%) - erupţii vasculitice. Peste 6 luni, artralgii şi mialgii au prezentat 17 şi 27 de pacienţi, respectiv. Artritele persistau la 1 an la 2 persoane, asociate cu factorul reumatoid şi anti-ССР pozitiv, la ambii fiind diagnosticată artrită reumatoidă. Din cei 3 pacienţi cu vasculită, erupţiile au dispărut peste 2 săptămâni la 2 persoane, iar la o pacientă erupţiile au evoluat către aspectul de purpură hemoragică, prezentând titru crescut de IgA şi CIC şi fiind diagnosticată cu vasculită IgA, care a recidivat după 2 ani. Concluzii. Observaţiile prezentate sugerează o posibilă conexiune între mecanismele patologice ale COVID-19 cu eventuale modificări imunologice, specifice bolilor autoimune reumatologice, iar consecinţele infecţiei pot persista pe termen lung.
Introduction. Infection with SARS-CoV-2 can manifest with rheumatologic symptoms, which can subsequently progress to a potential systemic disease. Objective. Long-term identification of rheumatologic morbid consequences in patients who have suffered from COVID-19. Methods. Fifty-eight patients, aged between 18 and 78 years, who experienced COVID-19 (2019-2022 years) and exhibited clinical rheumatic symptoms during active infection and convalescent period (> 2 weeks), were monitored for 6 months, 1 year, and 2 years. The severity of COVID-19 ranged from subclinical to severe forms with extensive pulmonary lesions. Results. During the active infection and convalescent period, predominated myalgia in 58 (100%) patients, arthralgia in 52 (89%), back pain in 44 patients (75.8%), arthritis in 5 patients (8.6%), and 3 patients (5.7%) presented with vasculitic eruptions. Over 6 months, arthralgia and myalgia were present in 17 and 27 patients, respectively. Arthritis persisted at 1 year in 2 individuals, associated with positive rheumatoid factor and anti-ССР; they were diagnosed with rheumatoid arthritis. Of the 3 patients with vasculitis, eruptions disappeared after 2 weeks in 2 individuals, while in one patient, eruptions progressed to a hemorrhagic purpura, presenting with elevated IgA and CIC titers and diagnosed with IgA vasculitis, which recurred after 2 years. Conclusions. The observations suggest a possible connection between the pathological mechanisms of COVID-19 and potential immunological changes specific to rheumatologic autoimmune diseases, with long-term persisting consequences of the infection.